-
Mashup Score: 0
A phase 1/2 trial investigating GRC 54276 for the treatment of patients with advanced solid tumors and lymphomas will begin following the acceptance of an investigational new drug application for the agent.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Oncology Nurse Advisor Summit - 1 year(s) agoSource: gateway.on24.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 0Oncology Nurse Advisor Summit - 1 year(s) agoSource: gateway.on24.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Oncology Nurse Advisor Summit - 1 year(s) agoSource: gateway.on24.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Intermittent dosing dramatically reduced myelosuppression that has hindered drug class
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 0JNCCN 360 - B-Cell Lymphomas - Front-Line Therapies With Liposomal Doxorubicin for Advanced B-Cell Lymphomas - 1 year(s) ago
By: Emily Rhode Posted: Wednesday, January 11, 2023 Claudia Giordano, MD, of Federico II University Medical School, Naples, and colleagues assessed the impact of a nonpegylated liposomal doxorubicin (NPDL) supercharge-driven strategy on interim fluorodeoxyglucose positron-emission tomography (FDG-PET) responses among…
Source: jnccn360.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0JNCCN 360 - B-Cell Lymphomas - Front-Line Therapies With Liposomal Doxorubicin for Advanced B-Cell Lymphomas - 1 year(s) ago
By: Emily Rhode Posted: Wednesday, January 11, 2023 Claudia Giordano, MD, of Federico II University Medical School, Naples, and colleagues assessed the impact of a nonpegylated liposomal doxorubicin (NPDL) supercharge-driven strategy on interim fluorodeoxyglucose positron-emission tomography (FDG-PET) responses among…
Source: jnccn360.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3
PURPOSE Mosunetuzumab is a bispecific antibody targeting CD20 and CD3 that redirects T cells to engage and eliminate malignant B cells and is being developed for relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs). METHODS This first-in-human trial (ClinicalTrials.gov identifier: NCT02500407) evaluated the safety and tolerability and efficacy of mosunetuzumab in patients with R/R…
Source: Journal of Clinical OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 4
Dr. Andrew Feldman and his team are helping to redefine the classification of T-cell lymphomas, an often fatal group of immune system tumors.
Categories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 2Next Generation Novel Agents for Aggressive B-Cell Lymphoma - 2 year(s) ago
A SOHO 2022 presentation by Jason Westin, MD will focus on t on 2 main categories of novel agents that manipulate the immune system to better target aggressive lymphomas.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
The #FDA accepted an IND application for GRC 54276 and the start of a phase 1/2, first-in-human, clinical study of GRC 54276 for the treatment of patients with advanced #solidtumors and #lymphomas. #lymsm https://t.co/BhA0mnmkj7